Analysis updated on Oct. 16, 2026 (UTC) · Alpha · vs marketSwitch to Total · Nasdaq
Our AI ranks Caredx, Inc. outside the neutral middle of its coverage (a directional signal). Create a free account and follow it to see the exact price target.
Caredx, Inc. is a mid-cap company with a market capitalization of $3.31B. It ranks number 10 by market capitalization among the 29 Services-Medical Laboratories issuers in our coverage with a current forecast. Its ROE of 26.1% is the highest of the 14 peers that report one.
For CDNA, the Spearman rank correlation between our 90-day forecasts and the returns that followed is 44.0%, measured on 357 forecast dates between 2022-07-29 and 2026-07-17 on this stock's own recent history. A rank correlation runs from -100% to +100%: it measures whether higher forecasts were followed by higher returns, and a value near zero or below means the model has shown little skill on this stock. On the 30-day forecasts the same correlation is 16.0%, measured on 400 forecast dates between 2022-07-29 and 2026-09-16. Across our coverage, the out-of-sample test on 4495 stocks from 2025-01-06 to 2026-07-07 produced a positive net return in 82.5% of rebalance periods (factor-neutral book, net of estimated costs). Full backtest report
Expected return relative to the market over the horizon: a positive alpha means the model expects the stock to beat the market, whatever the market does. Ratings: strong buy ≥ +1.8%, buy ≥ +0.2%, sell < -0.9%, strong sell < -1.2% (top 15%, next 20%, middle 30%, next 20%, bottom 15% of the 2026-10-16 signals)
A free account shows the exact forecast, rating and rank of 3 tickers you follow, CDNA included.
Follow CDNA free90D Alpha forecasts of every company scored, cut into five relative ratings at the 15th, 35th, 65th and 85th percentiles (dashed lines).
Trailing twelve months. The industry median and the rank (1 = highest) are taken over the Services-Medical Laboratories peers listed below that report each metric.
| Metric | CDNA | Rank |
|---|---|---|
| Market Cap | $3.31B | 10/29 |
| P/E Ratio | 34.98x | 3/6 |
| P/B Ratio | 7.78x | 5/22 |
| EPS | $1.83 | – |
| Book Value/Share | $8.23 | – |
| Revenue/Share | $8.85 | – |
| Metric | CDNA | Rank |
|---|---|---|
| ROE | 26.1% | 1/14 |
| ROA | 20.8% | 1/20 |
| ROIC | 24.3% | 3/24 |
| Operating Margin | 23.3% | 3/23 |
| Net Margin | 24.2% | 3/17 |
| EBT Margin | 25.1% | 3/23 |
| Tax Rate | 3.7% | – |
| Metric | CDNA | Rank |
|---|---|---|
| Current Ratio | 4.58x | 11/26 |
| Quick Ratio | 4.51x | 6/11 |
| D/E Ratio | 0.25x | 13/22 |
| Financial Leverage | 1.25x | 13/22 |
| Working Capital | $336M | 12/26 |
| Metric | CDNA | Rank |
|---|---|---|
| Operating Cash Flow | $94M | 8/27 |
| OCF Growth YoY | 428.5% | 1/7 |
| Metric | CDNA | Rank |
|---|---|---|
| Asset Turnover | 0.86x | 6/18 |
| Receivables Turnover | 13.3x | 2/19 |
| Fixed Assets Turnover | 17.1x | 3/17 |
| Days Sales Outstanding | 27 days | 18/19 |
| Metric | CDNA | Rank |
|---|---|---|
| Total Revenue | $458M | 9/19 |
| Operating Income | $107M | 3/26 |
| Net Income | $111M | 4/20 |
| R&D Expense | $80M | 8/20 |
| SG&A Expense | $322M | 8/20 |
| Metric | CDNA | Rank |
|---|---|---|
| Shares Outstanding | 52M | – |
| Net Income Growth | 114.8% | 2/5 |
| EPS Growth | 128.8% | 2/6 |
| Total Current Assets | $429M | 80.5% of assets |
| Cash & Short-term Investments | $374M | 70.1% of assets |
| Accounts Receivable | $34M | 6.5% of assets |
| Inventory | $7M | 1.3% of assets |
| Total Liabilities | $107M | 20.1% of assets |
| Short-term Debt | $84M | 15.8% of assets |
Companies classified under the same SEC industry code as Caredx, Inc. (Services-Medical Laboratories): 30 common-stock issuers with a forecast this week, one row per issuer, largest first. This is a classification match, not a curated list of competitors.
Reveal all forecasts · See exact % predictions for all competitors
Sign up free| Company | 90-Day AI Forecast (Alpha) | Market Cap |
|---|---|---|
| CDNA Caredx, Inc. | ▲ | $3.31B |
| NTRA Natera, Inc. | ▲ | $56.71B |
| DGX Quest Diagnostics Inc | ▼ | $25.94B |
| LH Labcorp Holdings Inc. | ▶ | $25.79B |
| GH Guardant Health, Inc. | ▲ | $21.28B |
| CAI Caris Life Sciences, Inc. | ▲ | $8.64B |
| RDNT Radnet, Inc. | ▶ | $5.41B |
| GRAL Grail, Inc. | ▲ | $5.26B |
| BLLN Billiontoone, Inc. | ▲ | $4.63B |
| VCYT Veracyte, Inc. | ▲ | $3.47B |
| CELC Celcuity Inc. | ▲ | $2.77B |
| FTRE Fortrea Holdings Inc. | ▶ | $2.14B |
| PSNL Personalis, Inc. | ▼ | $1.67B |
| FRNM Freenome, Inc. | ▶ | $1.26B |
| LMRI Lumexa Imaging Holdings, Inc. | ▶ | $1.04B |
| CSTL Castle Biosciences Inc | ▲ | $976M |
| FLGT Fulgent Genetics, Inc. | ▲ | $545M |
| BDSX Biodesix Inc | ▲ | $250M |
| XGN Exagen Inc. | ▲ | $187M |
| BNR Burning Rock Biotech Ltd | ▲ | $139M |
| SERA Sera Prognostics, Inc. | ▼ | $80M |
| CFOR Capforce Inc. | ▶ | $43M |
| MDXH Mdxhealth Sa | ▲ | $20M |
| AMS American Shared Hospital Services | ▼ | $9M |
| ADVB Advanced Biomed Inc. | ▶ | $7M |
| ACON Aclarion, Inc. | ▲ | $5M |
| BGLC Bionexus Gene Lab Corp | ▲ | $4M |
| LUDG Ludwig Enterprises, Inc. | ▼ | $670K |
| FCHS First Choice Healthcare Solutions, Inc. | ▶ | $260K |
| RNLXY Renalytix Plc | ▲ | N/A |
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
Hello, everyone. Thank you for joining us, and welcome to the CareDx Q4 2025 Financial Results Earnings Call. [Operator Instructions] I will now hand the call over to Caroline Corner Investor ...
CareDx, Inc. (Nasdaq: CDNA) – a leading precision medicine diagnostics company in transplant, specialty oncology, and cell therapy, today announced it will report financial results for the third ...
Our AI ranks Caredx, Inc. outside the neutral middle of its coverage (a directional signal). Create a free account and follow it to see the exact price target.
For CDNA, the Spearman rank correlation between our 90-day forecasts and the returns that followed is 44.0%, measured on 357 forecast dates between 2022-07-29 and 2026-07-17 on this stock's own recent history. A rank correlation runs from -100% to +100%: it measures whether higher forecasts were followed by higher returns, and a value near zero or below means the model has shown little skill on this stock. On the 30-day forecasts the same correlation is 16.0%, measured on 400 forecast dates between 2022-07-29 and 2026-09-16. Across our coverage, the out-of-sample test on 4495 stocks from 2025-01-06 to 2026-07-07 produced a positive net return in 82.5% of rebalance periods (factor-neutral book, net of estimated costs). Full backtest report
Caredx, Inc. forecasts are refreshed on trading days as the daily model run completes. The forecast on this page was produced on Oct. 16, 2026.
30 issuers in our coverage, CDNA included, share the SEC industry code Services-Medical Laboratories. The largest are: Natera, Inc. (NTRA), Quest Diagnostics Inc (DGX), Labcorp Holdings Inc. (LH), Guardant Health, Inc. (GH), Caris Life Sciences, Inc. (CAI), Radnet, Inc. (RDNT).
This analysis is generated automatically using our proprietary AI systems and should not be considered personalized investment advice. Past performance does not guarantee future results. Always conduct your own research and consider consulting a financial advisor before making investment decisions.
Signals, companies, plans: answered from live data.
I read Intratio's daily model signals, company data and your account to answer in seconds, in your language.